http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 18 Sep 2026 14:36:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Xenetic+Biosciences%2C+++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/27080172.html si-local-file:///var/storage/secattach/20260918/27080172.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Xenetic+Biosciences%2C+++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/27080172.html Fri, 18 Sep 2026 14:36:00 -0400 XBIO http://www.streetinsider.com/Corporate+News/Xenetic+Biosciences+to+acquire+Santersus+AG+in+all-stock+deal/27067292.html <p>Xenetic Biosciences, Inc. (NASDAQ: XBIO) and privately held Santersus AG have entered into a definitive share exchange agreement under which Xenetic will acquire all outstanding share capital of Santersus in an all-stock transaction, the companies announced on September 16, 2026.</p><p>Under the terms of the agreement, current Xenetic stockholders and Santersus equity holders would own approximately 15% and 85%, respectively, of the combined company on a fully diluted basis, subject to adjustment. The combined company is expected to trade on the Nasdaq Capital Market under the name Santersus Bio, Inc. with the ticker symbol "SNTS."</p><p>The transaction would combine Santersus' NucleoCapture® selective http://www.streetinsider.com/Corporate+News/Xenetic+Biosciences+to+acquire+Santersus+AG+in+all-stock+deal/27067292.html Wed, 16 Sep 2026 07:01:38 -0400 XBIO http://www.streetinsider.com/Mergers+and+Acquisitions/Xenetic+Biosciences+to+acquire+Santersus+AG+in+all-stock+deal/27067292.html <p>Xenetic Biosciences, Inc. (NASDAQ: XBIO) and privately held Santersus AG have entered into a definitive share exchange agreement under which Xenetic will acquire all outstanding share capital of Santersus in an all-stock transaction, the companies announced on September 16, 2026.</p><p>Under the terms of the agreement, current Xenetic stockholders and Santersus equity holders would own approximately 15% and 85%, respectively, of the combined company on a fully diluted basis, subject to adjustment. The combined company is expected to trade on the Nasdaq Capital Market under the name Santersus Bio, Inc. with the ticker symbol "SNTS."</p><p>The transaction would combine Santersus' NucleoCapture® selective http://www.streetinsider.com/Mergers+and+Acquisitions/Xenetic+Biosciences+to+acquire+Santersus+AG+in+all-stock+deal/27067292.html Wed, 16 Sep 2026 07:01:38 -0400 XBIO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Sep+14/27067290.html si-local-file:///var/storage/secattach/20260916/27067290.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Sep+14/27067290.html Wed, 16 Sep 2026 07:01:00 -0400 XBIO http://www.streetinsider.com/Press+Releases/Xenetic+Biosciences+and+Santersus+AG+Announce+Definitive+Share+Exchange+Agreement+to+Create+Global+Leader+in+NET-Targeting+Therapeutics/27067208.html <p><i><strong>Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplantation and oncology</strong></i></p><p><i><strong>Union of two companies brings together Santersus' NucleoCapture® technology, designed to physically remove NETs from circulation, with Xenetic's DNase technology, designed to enzymatically degrade NETs in tissue</strong></i></p><p><i><strong>Joint pipeline includes four first-in-class programs, including pivotal-stage programs in sepsis and systemic lupus erythematosus (SLE), both of which have received FDA Breakthrough Device Designation</strong></i></p><p><i><strong>Companies to host Business Update Conference Call and Webcast Today, Wednesday, September 16^th at 8:30 AM ET</strong></i></p> http://www.streetinsider.com/Press+Releases/Xenetic+Biosciences+and+Santersus+AG+Announce+Definitive+Share+Exchange+Agreement+to+Create+Global+Leader+in+NET-Targeting+Therapeutics/27067208.html Wed, 16 Sep 2026 07:00:00 -0400 XBIO http://www.streetinsider.com/ACCESS+Newswire/Xenetic+Biosciences+and+Santersus+AG+Announce+Definitive+Share+Exchange+Agreement+to+Create+Global+Leader+in+NET-Targeting+Therapeutics/27067208.html <p><i><strong>Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplantation and oncology</strong></i></p><p><i><strong>Union of two companies brings together Santersus' NucleoCapture® technology, designed to physically remove NETs from circulation, with Xenetic's DNase technology, designed to enzymatically degrade NETs in tissue</strong></i></p><p><i><strong>Joint pipeline includes four first-in-class programs, including pivotal-stage programs in sepsis and systemic lupus erythematosus (SLE), both of which have received FDA Breakthrough Device Designation</strong></i></p><p><i><strong>Companies to host Business Update Conference Call and Webcast Today, Wednesday, September 16^th at 8:30 AM ET</strong></i></p> http://www.streetinsider.com/ACCESS+Newswire/Xenetic+Biosciences+and+Santersus+AG+Announce+Definitive+Share+Exchange+Agreement+to+Create+Global+Leader+in+NET-Targeting+Therapeutics/27067208.html Wed, 16 Sep 2026 07:00:00 -0400 XBIO http://www.streetinsider.com/Press+Releases/Xenetic+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Strengthened+Scientific+Foundation+Supporting+Continued+Advancement+of+Proprietary+DNase+Platform/26888089.html <p><i><strong>Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy</strong></i></p><p><i><strong>Ongoing generation of translational data designed to support future clinical development and deepen understanding of DNase I-mediated NET targeting</strong></i></p><p><i><strong>Continued royalty generation provides recurring, non-dilutive funding to support continued investment in core development programs</strong></i></p> <p><strong id="dateline">FRAMINGHAM, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 7, 2026 / </strong><a rel="nofollow" href="https://pr.report/otuh">Xenetic Biosciences, Inc.</a> (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported financial results for the quarter ended June 30, 2026, and provided a corporate http://www.streetinsider.com/Press+Releases/Xenetic+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Strengthened+Scientific+Foundation+Supporting+Continued+Advancement+of+Proprietary+DNase+Platform/26888089.html Fri, 07 Aug 2026 08:35:00 -0400 XBIO http://www.streetinsider.com/ACCESS+Newswire/Xenetic+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Strengthened+Scientific+Foundation+Supporting+Continued+Advancement+of+Proprietary+DNase+Platform/26888089.html <p><i><strong>Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy</strong></i></p><p><i><strong>Ongoing generation of translational data designed to support future clinical development and deepen understanding of DNase I-mediated NET targeting</strong></i></p><p><i><strong>Continued royalty generation provides recurring, non-dilutive funding to support continued investment in core development programs</strong></i></p> <p><strong id="dateline">FRAMINGHAM, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 7, 2026 / </strong><a rel="nofollow" href="https://pr.report/otuh">Xenetic Biosciences, Inc.</a> (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported financial results for the quarter ended June 30, 2026, and provided a corporate http://www.streetinsider.com/ACCESS+Newswire/Xenetic+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Highlights+Strengthened+Scientific+Foundation+Supporting+Continued+Advancement+of+Proprietary+DNase+Platform/26888089.html Fri, 07 Aug 2026 08:35:00 -0400 XBIO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Aug+07/26888099.html si-local-file:///var/storage/secattach/20260807/26888099.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Aug+07/26888099.html Fri, 07 Aug 2026 08:35:00 -0400 LIFE O.00755272 O.13558872 XBIO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Aug+07/26888099.html si-local-file:///var/storage/secattach/20260807/26888099.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Aug+07/26888099.html Fri, 07 Aug 2026 08:35:00 -0400 LIFE O.00755272 O.13558872 XBIO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Aug+07/26888099.html si-local-file:///var/storage/secattach/20260807/26888099.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Aug+07/26888099.html Fri, 07 Aug 2026 08:35:00 -0400 LIFE O.00755272 O.13558872 XBIO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Aug+07/26888099.html si-local-file:///var/storage/secattach/20260807/26888099.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Xenetic+Biosciences%2C++++++For%3A+Aug+07/26888099.html Fri, 07 Aug 2026 08:35:00 -0400 LIFE O.00755272 O.13558872 XBIO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xenetic+Biosciences%2C++++++For%3A+Jun+30/26884726.html si-local-file:///var/storage/secattach/20260806/26884726.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xenetic+Biosciences%2C++++++For%3A+Jun+30/26884726.html Thu, 06 Aug 2026 16:32:00 -0400 LIFE O.00755272 O.13558872 XBIO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xenetic+Biosciences%2C++++++For%3A+Jun+30/26884726.html si-local-file:///var/storage/secattach/20260806/26884726.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xenetic+Biosciences%2C++++++For%3A+Jun+30/26884726.html Thu, 06 Aug 2026 16:32:00 -0400 LIFE O.00755272 O.13558872 XBIO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xenetic+Biosciences%2C++++++For%3A+Jun+30/26884726.html si-local-file:///var/storage/secattach/20260806/26884726.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xenetic+Biosciences%2C++++++For%3A+Jun+30/26884726.html Thu, 06 Aug 2026 16:32:00 -0400 LIFE O.00755272 O.13558872 XBIO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xenetic+Biosciences%2C++++++For%3A+Jun+30/26884726.html si-local-file:///var/storage/secattach/20260806/26884726.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Xenetic+Biosciences%2C++++++For%3A+Jun+30/26884726.html Thu, 06 Aug 2026 16:32:00 -0400 LIFE O.00755272 O.13558872 XBIO http://www.streetinsider.com/Corporate+News/Xenetic+Biosciences+partner+gets+Israeli+approval+for+lymphoma+study/26603074.html <p>Xenetic Biosciences Inc. (NASDAQ: XBIO) announced that its collaboration partner PeriNess Ltd. received approval from the Israeli Ministry of Health to conduct a clinical study combining DNase I with anti-CD19 CAR T cells in large B-cell lymphoma patients.</p><p>The exploratory study will treat 12 patients with stable or progressive disease prior to lymphodepletion therapy. Participants will receive CAR T cells targeting CD19 in combination with DNase I administered through 50-ml IV infusions at 1.0 mg/kg on days 0, 3, 6, 10 and 15 after CAR T cell infusion.</p><p>The study will evaluate clinical efficacy through objective response rate at 1 and 3 http://www.streetinsider.com/Corporate+News/Xenetic+Biosciences+partner+gets+Israeli+approval+for+lymphoma+study/26603074.html Thu, 04 Jun 2026 08:41:57 -0400 XBIO http://www.streetinsider.com/Press+Releases/Xenetic+Biosciences%2C+Inc.+Announces+That+Its+Collaboration+Partner+Received+Approval+From+the+Israeli+Ministry+of+Health+to+Conduct+Exploratory%2C+Investigator+Initiated+Study+of+DNase+I+In+Combination+/26603069.html <p><i><strong>Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion </strong></i></p><p><i><strong>Company reported strong positive preclinical results demonstrating significantly enhanced anti-tumor activity of anti-CD-19 CAR T cells when combined with DNase I in multiple preclinical models of hematologic cancers</strong></i></p><p><i><strong>Investigator initiated study to be conducted at Tel-Aviv Sourasky Medical Center ("Sourasky Center")</strong></i></p> <p><strong id="dateline">FRAMINGHAM, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 4, 2026 / </strong><a rel="nofollow" href="https://pr.report/kvr3">Xenetic Biosciences, Inc.</a> (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology http://www.streetinsider.com/Press+Releases/Xenetic+Biosciences%2C+Inc.+Announces+That+Its+Collaboration+Partner+Received+Approval+From+the+Israeli+Ministry+of+Health+to+Conduct+Exploratory%2C+Investigator+Initiated+Study+of+DNase+I+In+Combination+/26603069.html Thu, 04 Jun 2026 08:40:00 -0400 XBIO http://www.streetinsider.com/ACCESS+Newswire/Xenetic+Biosciences%2C+Inc.+Announces+That+Its+Collaboration+Partner+Received+Approval+From+the+Israeli+Ministry+of+Health+to+Conduct+Exploratory%2C+Investigator+Initiated+Study+of+DNase+I+In+Combination+/26603069.html <p><i><strong>Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion </strong></i></p><p><i><strong>Company reported strong positive preclinical results demonstrating significantly enhanced anti-tumor activity of anti-CD-19 CAR T cells when combined with DNase I in multiple preclinical models of hematologic cancers</strong></i></p><p><i><strong>Investigator initiated study to be conducted at Tel-Aviv Sourasky Medical Center ("Sourasky Center")</strong></i></p> <p><strong id="dateline">FRAMINGHAM, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 4, 2026 / </strong><a rel="nofollow" href="https://pr.report/kvr3">Xenetic Biosciences, Inc.</a> (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology http://www.streetinsider.com/ACCESS+Newswire/Xenetic+Biosciences%2C+Inc.+Announces+That+Its+Collaboration+Partner+Received+Approval+From+the+Israeli+Ministry+of+Health+to+Conduct+Exploratory%2C+Investigator+Initiated+Study+of+DNase+I+In+Combination+/26603069.html Thu, 04 Jun 2026 08:40:00 -0400 XBIO http://www.streetinsider.com/Corporate+News/Xenetic+Biosciences+presents+DNase+I+data+at+ASCO+2026+meeting/26580394.html <p>Xenetic Biosciences Inc. (NASDAQ: XBIO) presented preclinical data at the 2026 American Society of Clinical Oncology Annual Meeting showing that DNase I enhances CAR-T cell function in hematologic cancer models.</p><p>The poster presentation, titled "Targeting cfDNA and NETs with DNase I Augments CAR T-Cell Function and Antitumor Efficacy," was presented on June 1, 2026, by Alexey V. Stepanov, PhD.</p><p>According to the company's findings, DNase I degraded extracellular DNA and preserved CAR-T cell function in laboratory studies. The treatment improved CD8-positive T cell ratios and reduced expression of exhaustion markers including PD-1, LAG-3 and TIM-3 across multiple rounds of tumor rechallenge in http://www.streetinsider.com/Corporate+News/Xenetic+Biosciences+presents+DNase+I+data+at+ASCO+2026+meeting/26580394.html Mon, 01 Jun 2026 09:03:36 -0400 XBIO http://www.streetinsider.com/FDA/Xenetic+Biosciences+presents+DNase+I+data+at+ASCO+2026+meeting/26580394.html <p>Xenetic Biosciences Inc. (NASDAQ: XBIO) presented preclinical data at the 2026 American Society of Clinical Oncology Annual Meeting showing that DNase I enhances CAR-T cell function in hematologic cancer models.</p><p>The poster presentation, titled "Targeting cfDNA and NETs with DNase I Augments CAR T-Cell Function and Antitumor Efficacy," was presented on June 1, 2026, by Alexey V. Stepanov, PhD.</p><p>According to the company's findings, DNase I degraded extracellular DNA and preserved CAR-T cell function in laboratory studies. The treatment improved CD8-positive T cell ratios and reduced expression of exhaustion markers including PD-1, LAG-3 and TIM-3 across multiple rounds of tumor rechallenge in http://www.streetinsider.com/FDA/Xenetic+Biosciences+presents+DNase+I+data+at+ASCO+2026+meeting/26580394.html Mon, 01 Jun 2026 09:03:36 -0400 XBIO http://www.streetinsider.com/Press+Releases/Xenetic+Biosciences+Showcases+Compelling+ASCO+2026+Data+Demonstrating+DNase+I+Significantly+Enhances+CAR-T+Cell+Persistence%2C+Tumor+Control%2C+and+Survival/26580366.html <p><i><strong>New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies</strong></i></p><p><i><strong>Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models</strong></i></p><p><i><strong>Findings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers</strong></i></p><p><i><strong>Data to be presented today as a poster presentation at the ASCO 2026 annual meeting</strong></i></p> <p><strong id="dateline">FRAMINGHAM, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 1, 2026 / </strong><a rel="nofollow" href="https://pr.report/m2km">Xenetic Biosciences, Inc.</a> (NASDAQ:XBIO) ("Xenetic" http://www.streetinsider.com/Press+Releases/Xenetic+Biosciences+Showcases+Compelling+ASCO+2026+Data+Demonstrating+DNase+I+Significantly+Enhances+CAR-T+Cell+Persistence%2C+Tumor+Control%2C+and+Survival/26580366.html Mon, 01 Jun 2026 09:02:00 -0400 XBIO http://www.streetinsider.com/ACCESS+Newswire/Xenetic+Biosciences+Showcases+Compelling+ASCO+2026+Data+Demonstrating+DNase+I+Significantly+Enhances+CAR-T+Cell+Persistence%2C+Tumor+Control%2C+and+Survival/26580366.html <p><i><strong>New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies</strong></i></p><p><i><strong>Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models</strong></i></p><p><i><strong>Findings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers</strong></i></p><p><i><strong>Data to be presented today as a poster presentation at the ASCO 2026 annual meeting</strong></i></p> <p><strong id="dateline">FRAMINGHAM, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 1, 2026 / </strong><a rel="nofollow" href="https://pr.report/m2km">Xenetic Biosciences, Inc.</a> (NASDAQ:XBIO) ("Xenetic" http://www.streetinsider.com/ACCESS+Newswire/Xenetic+Biosciences+Showcases+Compelling+ASCO+2026+Data+Demonstrating+DNase+I+Significantly+Enhances+CAR-T+Cell+Persistence%2C+Tumor+Control%2C+and+Survival/26580366.html Mon, 01 Jun 2026 09:02:00 -0400 XBIO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Xenetic+Biosciences%2C+++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/26575016.html si-local-file:///var/storage/secattach/20260529/26575016.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Xenetic+Biosciences%2C+++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/26575016.html Fri, 29 May 2026 16:05:00 -0400 LIFE O.00755272 O.13558872 XBIO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Xenetic+Biosciences%2C+++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/26575016.html si-local-file:///var/storage/secattach/20260529/26575016.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Xenetic+Biosciences%2C+++++++++++++++++++Filed+by%3A+MJL+Manager+LLC/26575016.html Fri, 29 May 2026 16:05:00 -0400 LIFE O.00755272 O.13558872 XBIO